This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

(Rev.	RECORDATION FORM	Patent and Trademark Office							
OME	3 No 0651-0011 (exp. 4/94) PATENTS	ONLY BOX ASSIGNMENTS							
	To the Honorable Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy thereof.								
1.	Name of conveying party(ies):	2. Name and address of receiving party(ies):							
	Atsuo Kuki, Xinqiang Li, Michael Bruno Plewe, Hai	Name: Agouron Pharmaceuticals, Inc.							
	Wang, Junhu Zhang	Internal Address: Patent Department							
Add	litional name(s) of conveying party(ies) attached? Yes No								
3.	Nature of Conveyance:	Street Address: 10777 Science Center Drive							
	Security Agreement Change of Name	City: San Diego State: CA ZIP: 92121							
	Other	Additional name(s) & address(es) attached? Yes No							
Eye	cution Date(s): Feb. 11, 2003, Feb. 12, 2003, Feb. 14,2	2023							
4.	Application number(s) or patent number(s):								
	If this document is being filed together with a new application	n, the execution date of the application is:							
	A. Patent Application No.(s) 60/443,223	B. Patent No.(s)							
<u> </u>	Additional numbers attached	d? 🗌 Yes 🔯 No							
5.	Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved: 1							
	Name: Jeffrey Rennecker	7. Total fee (37 CFR 3.41)							
	Internal Address: Pfizer, Inc.	☐ Enclosed							
	Street Address: 10777 Science Center Drive	Authorized to be charged to deposit account							
		8. Deposit account number:500329							
	City: San Diego State: CA ZIP: 92121	(Attach duplicate copy of this page if paying by deposit account)							
	DO NOT USE THIS SPACE								
9.	Statement and signature.								
	To the best of my knowledge and belief, the foregoing inform true copy of the original document.	nation is true and correct and any attached copy is a							
	Jeffrey W. Rennecker (Reg. 40,784) Name of Person Signing	Signature February 18, 2003 Date							
	Total number of pages including cover s	sheet, attachments, and document:10							

Name of receiving party(ies): (C ntinued)
 Pfizer Inc.

Street Address: 235 East 42nd Street

City: New York State: NY ZIP: 10017

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged, we, Atsuo Kuki of 1261 Rancho Encinitas Drive, Encinitas, California 92024; Xinqiang Li of 9372 Beak Point, San Diego, California 92129; Michael Bruno Plewe of 4711 Caminito Avenue, San Diego, California 92130; Hai Wang of 11087 Ice Skate Place, San Diego, California 92126; and Junhu Zhang of 3445 Lebon Drive #1423, San Diego, California 92122, respectively, hereby sell, assign and transfer unto AGOURON PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of California, United States of America, and having a place of business at 10777 Science Center Drive, San Diego, California 92121, United States of America, our entire right, title and interest, except as limited herein below, in and to provisional patent application of the United States of America, having PFIZER INC. Docket No.: PC025050, entitled HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE; filed in the United States Patent and Trademark Office on January 27, 2003 and assigned application number 60/443,223; and our entire right, title and interest, in the United States of America, in and to all our inventions, whether joint or sole, disclosed in said patent application; and our entire right, title and interest in and to all applications filed in the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted in the United States of America on the foregoing applications;

and we hereby sell, assign and transfer unto PFIZER INC., a corporation organized and existing under the laws of the State of Delaware, United States of America, and having a place of business at 235 East 42nd Street, New York, New York 10017, United States of America, our entire right, title and interest, in all countries of the world except the United States of America, in and to all our inventions, whether joint or sole, disclosed in said provisional patent application; and our entire right, title and interest in and to all patent applications filed outside the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted outside the United States of America on said patent applications filed outside the United States of

Provisional Assignment – Joint
PC025051
Page 2 of 4

America; and the right to claim priority from said provisional patent application under the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States of America is a party and which afford similar priority-claiming privileges, in all countries of the world except the United States of America;

and we hereby agree, whenever requested, to communicate to said AGOURON PHARMACEUTICALS, INC. and said PFIZER INC., and their successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding respecting said inventions, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in all countries of the world.

Signed and witnessed this	day of	at .
,	Atsuo Kuki	
In the presence of:		
		
Inrint name here sign shovel		

Provisional Assignment – Joint PC025051
Page 3 of 4

Signed and witnessed this Feb 14	day of 2003	at
Signed and witnessed this Feb 14 11099 N. Torrey Pines	s La Jolla (192037	
,	Xinqiang Li	
In the presence of:		
Erguang Li	Sign	
[print name here, sign above]		
Signed and witnessed this	day of	at -
	Michael Bruno Plewe	
In the presence of:		
[print name here, sign above]		

Provisional Assignment – Joint **PC025051**Page 4 of 4

Signed and witn ssed this	day of	at
	Hai Wang	
In the presence of:	•	
		
[print name here, sign above]		
Signed and witnessed this	day of	at
	Junhu Zhang	
In the presence of:		
Inrint name here sign abovel		

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged, we, Atsuo Kuki of 1261 Rancho Encinitas Drive, Encinitas, California 92024; Xinqiang Li of 9372 Beak Point, San Diego, California 92129; Michael Bruno Plewe of 4711 Caminito Avenue, San Diego, California 92130; Hai Wang of 11087 Ice Skate Place, San Diego, California 92126; and Junhu Zhang of 3445 Lebon Drive #1423, San Diego, California 92122, respectively, hereby sell, assign and transfer unto AGOURON PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of California, United States of America, and having a place of business at 10777 Science Center Drive, San Diego, California 92121, United States of America, our entire right, title and interest, except as limited herein below, in and to provisional patent application of the United States of America, having PFIZER INC. Docket No.: PC025050, entitled HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE; filed in the United States Patent and Trademark Office on January 27, 2003 and assigned application number 60/443,223; and our entire right, title and interest, in the United States of America, in and to all our inventions, whether joint or sole, disclosed in said patent application; and our entire right, title and interest in and to all applications filed in the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted in the United States of America on the foregoing applications;

and we hereby sell, assign and transfer unto PFIZER INC., a corporation organized and existing under the laws of the State of Delaware, United States of America, and having a place of business at 235 East 42nd Street, New York, New York 10017, United States of America, our entire right, title and interest, in all countries of the world except the United States of America, in and to all our inventions, whether joint or sole, disclosed in said provisional patent application; and our entire right, title and interest in and to all patent applications filed outside the United States of America for Letters Patent for any or all of said inventions; and our entire right, title and interest in and to all Letters Patent granted outside the United States of America on said patent applications filed outside the United States of

Provisional Assignment – Joint
PC025051
Page 2 of 4

America; and the right to claim priority from said provisional patent application under the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States of America is a party and which afford similar priority-claiming privileges, in all countries of the world except the United States of America;

and we hereby agree, whenever requested, to communicate to said AGOURON PHARMACEUTICALS, INC. and said PFIZER INC., and their successors and assigns, any facts known to us respecting said inventions, to testify in any legal proceeding respecting said inventions, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in all countries of the world.

Signed	and	witnessed	this
Sidiled	allu	Minicasca	นแจ

1).**/ /**(day c

at

Atsuo Kuki

In the presence of:

[print name here, sign above]

Provisional Assignment – Joint PC025051
Page 3 of 4

Signed and witnessed this	day of -	at	
In the presence of:	Xinqiang Li		
[print name here, sign above]			
Signed and witnessed this 12 th Sar Diego CA USA	day of February	at	
•	flutual Brew Ple	حسو	
	Michael Bruno Plewe		
In the presence of:			
Danille Dyon			
Danielle Dixon			
[print name here, sign above]			

Provisional Assignment – Joint PC025051 Page 4 of 4

Signed and witnessed this (2 day of + ebrury at
Signed and witnessed this 12 day of tebrury at 20 San Diego, Chi 92126
Hai Wang
In the presence of:
Danill Dyon
Danielle Dixon
[print name here, sign above]
Signed and witnessed this 12 day of Feb, 2003 at San Diego, CA 92122
Junhu Zhang Memy
In the presence of:
Danill Diger
Danielle Dixon
[print name here, sign above]

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Applica	Application Number			To be assigned		
			Filing Date			Herewith		
POWER OF	POWER OF ATTORNEY			First Named Inventor				
and CORRESPONDENCE ADDRESS			Title			GRASE INHIBIT CEUTICAL COI S FOR THEIR U	MPOSITIONS, AND	
INDICATION		Art Uni	t		To be as	-		
INDIOATION I OKI			er Name		To be as	ssigned		
	Attorne	y Docket	Number	PC2505	51A			
I hereby appoint:								
Practitioners at Custor	mer Number	289	40					
OR OR	L	_						
Practitioners named be	elow:							
	Name			Registrati	on Numb	er		
		-	<u> </u>					
•								
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.								
Please recognize or change	-			l application to	· · · · · · · · · · · · · · · · · · ·			
	•	SSS TOT LITE ADDV	s-identined	і аррасацоп ц	.			
The above-mentioned	Customer Number.							
OR				 1				
The address associate	ed with Customer Number							
OR		•						
Firm or Individual Name								
Address							· · · · · · · · · · · · · · · · · · ·	
Address								
City			State		Zip	•		
Country	· - · · · · · · · · · · · · · · · · · · ·							
Telephone		F	ax				·	
I am the: Applicant/Inventor. Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).								
	SIGNATURE o			ee of Recor	d			
Name	ATSUO KUKI	70	11					
Signature	1	low the	2					
Date	D.	0. /	207				•	
NOTE: Signatures of all the inve				their represer	itative(s) a	re required. S	ubmit multiple	
forms if more than one signature is required, see below*.								

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

★ Total of 5 forms are submitted.

PTO/SB/81(06-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

		L	Filling Date		nerewiti	11	
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS			irst Named I	nventor	ATSUO	KUKI	
			litle .		PHARMA	HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE	
	ON FORM	7	Art Unit		To be as		
MBIOAII					To be as	ssigned	
					PC2505	51A	
I hereby appoint:							
Practitioners at Custo	mer Number		28940				
OR		L					
Practitioners named t	nelow:						
	Name			Registra	tion Numb)er	l
	Titaline.			TREGISTIO	THOM INDINE	Je!	
			•	· · · - · · -			•
as my/our attorney(s) or age business in the United State					ct all		
Please recognize or change					to:		
_	·	000 101 111	0 45010 16011	шов арриовиог			
The above-mentioned	Customer Number.						
OR							
The address associat	ed with Customer Number						
OR							
Firm or Individual Name							
	<u> </u>			•			
Address							
Address							
City			State	<u> </u>	Zip		
Country							
Telephone			Fax			 	
I am the:							
Applicant/Inventor.							
Assignee of record of the entire interest. See 37 CFR 3.71.							
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). SIGNATURE of Applicant or Assignee of Record							
Name	MICHAEL BRUNO P						
· · · · · · · · · · · · · · · · · · ·	Marked Bru		Carro			·	
Signature Date	15 Dec 2003	· · · · · ·	· · · · · · · · · · · · · · · · · · ·				
NOTE: Signatures of all the inv forms if more than one signature		ord of the	entire interes	t or their repres	entative(s) a	re required. S	ubmit multiple
ionno il more man one signatur	o io required, ace below .						

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

★ Total of 5 forms are submitted.

Herewith

PTO/SB/81(06-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Filing Date

Application Number

		,					
POWER OF ATTORNEY			First Named Inventor		ATSUO KUKI		
ar	nd ENCE ADDRESS		Title		HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE		
	ON FORM	ſ	Art Unit		To be assigned		
HUUAIN			Examiner Nar	me	To be assigned		
			Attorney Doc	ket Number	PC25051A		
I hereby appoint:							
Practitioners at Custon	mer Number		28940				
OR		Щ	<u> </u>				
Practitioners named b	aniow.						
	Name			Pogietra	tion Number		
	Hame			Reulatia	tion Number		
as my/our attorney(s) or age business in the United State:	int(s) to prosecute the app	lication	identified above	e, and to transac	ct all		
Please recognize or change							
		ess ioi i	the above-lue in	ified application	to:		
The above-mentioned	Customer Number.						
OR				·			
The address associate	ed with Customer Number	r					
OR .		L					
							
Firm or Individual Name							
Address							
Address							
City			State		Zip		
Country							
Telephone			Fax				
I am the:				L			
Applicant/Inventor.							
	the entire interest. See 37 CFR 3.73(b) is enclosed. (F						
	SIGNATURE (of App	licant or Assi	gnee of Reco	ord		
Name	XINQIANG LI						
Signature	1500	ア:					
Date	12-06-	· 200	, ろ				
NOTE: Signatures of all the inve	entors or assignees of reco			or their represe	entative(s) are required. Submit multiple		
forms if more than one signature	· · · · · · · · · · · · · · · · · · ·						
Total of <u>5</u> forms are submitted.							

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/81(06-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

		Filing Date		Herewith	l			
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS			First Nar	ned Inv	entor	ATSUO I	ATSUO KUKI	
			Title			PHARMA	GRASE INHIBI CEUTICAL CO G FOR THEIR I	MPOSITIONS, AND
		Ī	Art Unit			To be as		
INDICATION FORM			Examine	r Name)	To be as	signed	
		1	Attorney	Docke	t Number	PC2505	1A	
I hereby appoint:								
	mer Number		2894	0				
Practitioners at Custoi OR		L	2074					
Practitioners named b	elow:							
Traditioners named b	Name		Ī	-	Pogietrat	ion Numb	<u> </u>	1
	Name		_	-	Redistrat	ion idamo	<u> </u>	•
]
								-
	<u> </u>							1
as my/our attorney(s) or age business in the United State:	nt(s) to prosecute the app	dication	identified a	above, a	and to transac	t all		
Please recognize or change	•	ess for	tne above-	identine	ed application	ю:		
The above-mentioned	Customer Number.							
OR								
The address associate	ed with Customer Number							
OR		L						
								
Firm or Individual Name								
Address			 -					
Address							······································	
City			Si	ate		Zip		****
Country			.					
Telephone			Fa	×				
I am the:								
Applicant/Inventor.								
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).								
	SIGNATURE			Assig	nee of Reco	rd		
Name HAI WANG								
Signature								
Date	De	c. 9) . a	<u>ං</u>				
NOTE: Signatures of all the inve	entors or assignees of rec					ntative(s) a	re required.	Submit multiple

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

★ Total of 5 forms are submitted.

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

			Filing Date		Herewith		
POWER OF ATTORNEY and CORRESPONDENCE ADDRESS			First Named Inventor		ATSUO KUKI		
			Title			ASE INHIBITORS, UTICAL COMPOSITIONS, AND OR THEIR USE	
INDICATION FORM				•	To be assig		
INDICATION FO	Examin	er Name		To be assig	gned		
	Attorne	y Docket N	Number	PC25051A	4		
I hereby appoint:		*					
	.har	2894	40	1			
	ibei	2094	•••				
OR							
Practitioners named below:							
	Name			Registrati	on Number		
 		··· - · · · · · · · · · · · · · · · · · · ·		 			
			<u> </u>				
as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.							
Please recognize or change the corr		-		application t	0.		
<u></u>	·		, identified	арриоской с	o .		
The above-mentioned Custom	er Number.						
OR				_			
The address associated with 0	Customer Number			ŀ			
OR							
Firm or Individual Name							
Address	· · · · · · · · · · · · · · · · · · ·	<u>-</u>					
Address							
City		8	State		Zip		
Country						·	
Telephone		Fa	эx				
I am the:						-	
Applicant/Inventor.							
	Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).						
	SIGNATURE of	-		e of Reco	rd		
Name JUNH	U ZHANG						
Signature	de	ev.		RO			
Date	Te	e. 9. 7	2007	3			
NOTE: Signatures of all the inventors or forms if more than one signature is requ					ntative(s) are	required. Submit multiple	

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

★ Total of 5 forms are submitted.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

CHINA

Citizen of

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number. DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)** As the below named inventor(s), I/we declare that: This declaration is directed to: The attached application, or Application No. _____, filed on _____ as amended on _____ (if applicable); I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought; I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above; I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application. All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon. Full Name of inventor(s) Inventor 1 **ATSUO KUKI** US Signature Citizen of Inventor 2 XINQIANG LI Signature Citizen of Inventor 3 MICHAEL BRUNO PLEWE Citizen of US GERMAN Signature Inventor 4 **HAI WANG**

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) As the below named inventor(s), I/we declare that: This declaration is directed to: M The attached application, or Application No. _____, filed on ___ as amended on _____ (if applicable); I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought; I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above; I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application. All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon. Full Name of Inventor(s) Inventor 1 **ATSUO KUKI** US Signature Citizen of Inventor 2 XINQIANG LI US Signature Citizen of Inventor 3 MICHAEL BRUNO PLEWE US Signature Citizen of Inventor 4 **HAI WANG CHINA** Signature Citizen of

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN **APPLICATION DATA SHEET (37 CFR 1.76)** As the below named inventor(s), I/we declare that: This declaration is directed to: The attached application, or Application No. _____, filed on _____ as amended on (if applicable); I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought; I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above; I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application. All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon. Full Name of Inventor(s) Inventor 5 **JUNHU ZHANG** Signature Citizen of

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Additional inventors are being named on